Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Dupixent (dupilumab) is a brand-name injection that’s prescribed for treating asthma. This article covers topics such as side effects, dosage, and how Dupixent works. Dupixent is available as a ...

Dupixent pen and Dupixent syringe are used to give Dupixent doses by subcutaneous injection. Dupixent pen and syringe share several features but also have some differences, including needle ...

These drugs inhibit interleukin (IL)-5, while Dupixent inhibits IL-4 and IL-13, but can be considered a rival because it is also an injection. Patients may opt to take the others because of their ...

Adverse events more commonly observed with Dupixent compared to placebo were injection site reactions and COVID-19 infection. Published first on TheFly – the ultimate source for real-time ...

Global healthcare company Sanofi and Regeneron Pharmaceuticals today announced that the US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) injection to patients suffering from ...

Dupixent (dupilumab ... The IL-4 and IL-13 targeting antibody is administered as a subcutaneous injection every other week after an initial loading dose, and can be used with or without topical ...

Some of the more common problems with Dupixent, for example. are: Irritation at the injection site Infection with herpes simplex virus Eye problems such as blurred vision or eye redness ...

One primary reason is the strong performance and potential of Dupixent, which is expected to partially counterbalance the uncertainties surrounding Eylea. The expected growth in Dupixent’s ...

Dupixent ® is now used to treat over a million patients globally, with continued growth and expansion in multiple indications for diseases in which type 2 inflammation plays a role EYLEA HD ...